Observational Study for Real-time Detection of Melanoma Cells
This study is looking at a new device that can detect melanoma cells in your blood in real-time. This device, called a Photoacoustic flow cytometry (PAFC)-based prototype, aims to find these circulating tumor cells (CTCs) more effectively than current methods. The study will enroll 75 participants, including healthy individuals and those with early or advanced melanoma. The main goal is to see how many participants have these circulating tumor cells after 14-21 days. You may be able to join if you are between 18 and 80 years old and have a confirmed diagnosis of melanoma.
- Study design
- This is an observational study with a planned enrollment of 75 participants, divided into three groups: healthy controls, advanced-stage melanoma, and early-stage melanoma.
- What's involved
- You must be able to sit still for 90 minutes. The record does not specify other visits or procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 14-21 days, which suggests a short follow-up period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
In Vivo Real-time Detection of Circulating Melanoma Cells
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jumin Sunde, MD · PRINCIPAL_INVESTIGATOR · University of Arkansas
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of participants that possess circulating tumor cells.14-21 days